Hope for MSA patients: continued access to experimental drug ATH434
Disease control
AVAILABLE
This program offers ongoing access to the experimental drug ATH434 for people with multiple system atrophy (MSA) who completed a prior Phase 2 study. Participants take the drug twice daily by mouth. The goal is to allow continued treatment for those who may benefit, as judged by …
Sponsor: Alterity Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC